$Novavax(NVAX.US)$ Novavax has significantly underperformed establishe...

$Novavax(NVAX.US)$ Novavax has significantly underperformed established vaccine makers so far this year, failing to replicate its stellar performance in 2020, when its stock soared more than 270-fold amid strong expectations for COVID-19 vaccines. After several delays, the company has yet to apply for US regulatory approval for its coronavirus vaccine. Novavax CEO Stanley Erck said in a recent earnings call that the full regulatory proposal for the coronavirus vaccine in the United States will be submitted to the FDA by the end of the year.